Journal of the American Veterinary Medical Association · 2025
Efficacy of enflicoxib for postoperative pain and inflammation in soft tissue surgery in dogs: a multicenter and randomized clinical field trial.
СтатьяМногоцентровое исследованиеRandomized Controlled Trial, VeterinaryClinical Trial, VeterinaryПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Salichs Marta, Blasco Anabel, Badiella Llorenç, Costa-Farré Cristina, Sousa Pedro, Homedes Josep
Аннотация
OBJECTIVE: To demonstrate that a single dose of enflicoxib is noninferior to daily carprofen for the control of pain and inflammation in dogs undergoing soft tissue surgery.
METHODS: A prospective, multisite, blinded, randomized, controlled, parallel-group, noninferiority field study was performed to assess the efficacy and safety of enflicoxib in the control of pain and inflammation associated with soft tissue surgery. Two hundred fifteen dogs were randomized to receive 8 mg/kg of enflicoxib PO the day before surgery or 4 mg/kg of carprofen SC at induction and PO daily for 5 days. Veterinarians assessed efficacy with the short form of the Glasgow Composite Pain Scale (SF-GCPS) at 2, 5, 8, and 24 hours and 2, 3, and 5 days after surgery. The visual analog scale was used to assess inflammation. Demeanor, analgesia, and mobility were assessed daily by the owners.
RESULTS: Enflicoxib was noninferior to carprofen in the SF-GCPS area under the curve for the first 48 hours. Inflammation and SF-GCPS total scores were within the clinically relevant margin at each time point. No differences were observed in inflammation or in the owner assessment.
CONCLUSIONS: Enflicoxib administered 24 hours before surgery is safe and efficacious for the control of postoperative pain associated with soft tissue surgery.
CLINICAL RELEVANCE: A single preoperative dose of enflicoxib is an alternative for postoperative management in dogs undergoing soft tissue surgery, offering a simplified treatment regimen without compromising outcomes.
METHODS: A prospective, multisite, blinded, randomized, controlled, parallel-group, noninferiority field study was performed to assess the efficacy and safety of enflicoxib in the control of pain and inflammation associated with soft tissue surgery. Two hundred fifteen dogs were randomized to receive 8 mg/kg of enflicoxib PO the day before surgery or 4 mg/kg of carprofen SC at induction and PO daily for 5 days. Veterinarians assessed efficacy with the short form of the Glasgow Composite Pain Scale (SF-GCPS) at 2, 5, 8, and 24 hours and 2, 3, and 5 days after surgery. The visual analog scale was used to assess inflammation. Demeanor, analgesia, and mobility were assessed daily by the owners.
RESULTS: Enflicoxib was noninferior to carprofen in the SF-GCPS area under the curve for the first 48 hours. Inflammation and SF-GCPS total scores were within the clinically relevant margin at each time point. No differences were observed in inflammation or in the owner assessment.
CONCLUSIONS: Enflicoxib administered 24 hours before surgery is safe and efficacious for the control of postoperative pain associated with soft tissue surgery.
CLINICAL RELEVANCE: A single preoperative dose of enflicoxib is an alternative for postoperative management in dogs undergoing soft tissue surgery, offering a simplified treatment regimen without compromising outcomes.